← Leaderboards
Kenneth H. Yu
Sloan-Kettering Inst Can Research
$4,069,136
Attributed
$8,483,393
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2011–21$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$8,483,393 · 4
By mechanism
R01$7,942,291 · 3
K08$541,102 · 1
Top collaborators
- Paul Tempst5 shared
- John L Humm3 shared
- Brian J. Mccarthy3 shared
- Abraham Wu3 shared
- Nagavarakishore Pillarsetty2 shared
- Mark Ricigliano2 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Richard N Kolesnick$17,601,323
- Nancy Y Lee$8,718,881
- Pankaj Chaturvedi$1,198,588
- Thomas Reiner$4,804,085
- Alice Chia- Chi Wei$2,617,533
Others in their field
Top investigators on “Malignant Neoplasm Of Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Anirban Maitra · Johns Hopkins University$43,028,398
- Walter John Curran · Thomas Jefferson University$26,641,549
- Surinder Kumar Batra · University Of Pittsburgh At Pittsburgh$26,074,679
- Michael A Hollingsworth · University Of Nebraska Medical Center$23,837,917
- Robert E Reiter · University Of California Los Angeles$21,473,394
Research focus
Malignant Neoplasm Of PancreasInnovationTumorCancer EtiologyBaseMalignant NeoplasmsPancreatic Ductal AdenocarcinomaTissuesTumor TissueInsightMalignant Breast NeoplasmBiologicalPathway InteractionsNeoplasm MetastasisCessation Of LifeCellsMortalityColorectal CancerEarly DiagnosisGeneticPancreasBiologyPerformanceLaboratories
Grant awards (16)
Protein and proteolytic activity biomarkers of early stage pancreatic cancer$623,472
R01 · FY2021 · CA
Protein and proteolytic activity biomarkers of early stage pancreatic cancer$623,472
R01 · FY2020 · CA
Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer$575,997
R01 · FY2020 · CA · contact PI
Imaging drug uptake and distribution in chemoradiation therapy of pancreatic cancer$671,441
R01 · FY2019 · CA
Protein and proteolytic activity biomarkers of early stage pancreatic cancer$614,311
R01 · FY2019 · CA
Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer$558,719
R01 · FY2019 · CA · contact PI
Imaging drug uptake and distribution in chemoradiation therapy of pancreatic cancer$660,603
R01 · FY2018 · CA
Protein and proteolytic activity biomarkers of early stage pancreatic cancer$618,868
R01 · FY2018 · CA
Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer$558,143
R01 · FY2018 · CA · contact PI
Imaging drug uptake and distribution in chemoradiation therapy of pancreatic cancer$660,603
R01 · FY2017 · CA
Protein and proteolytic activity biomarkers of early stage pancreatic cancer$642,526
R01 · FY2017 · CA
Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer$558,143
R01 · FY2017 · CA · contact PI
Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer$575,993
R01 · FY2016 · CA · contact PI
Biomarkers of exposure and response to environmental tobacco smoke in the pancrea$179,734
K08 · FY2013 · ES · contact PI
Biomarkers of exposure and response to environmental tobacco smoke in the pancrea$180,684
K08 · FY2012 · ES · contact PI
Biomarkers of exposure and response to environmental tobacco smoke in the pancrea$180,684
K08 · FY2011 · ES · contact PI